Evidence map›Paper›PMID 35537738›Full record

ArticleBMJ (Clinical research ed.)2022

Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for covid-19: meta-epidemiological study.

Osman Moneer, Garrison Daly, Joshua J Skydel, Kate Nyhan, Peter Lurie, Joseph S Ross, Joshua D Wallach

Abstract read
In one paragraph

Article in BMJ (Clinical research ed.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Osman MoneerYale School of Medicine, Yale University, New Haven, CT, USA.
Garrison DalyCenter for Science in the Public Interest, Washington, DC, USA.
Joshua J SkydelDartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
Kate NyhanHarvey Cushing/John Hay Whitney Medical Library, Yale University, New Haven, CT, USA.
Peter LurieCenter for Science in the Public Interest, Washington, DC, USA.
Joseph S RossSection of General Medicine and the National Clinician Scholars Program, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Joshua D WallachDepartment of Environmental Health Sciences, Yale School of Public Health, New Haven, CT, USA Joshua.wallach@yale.edu.ORCID 0000-0002-2816-6905

Funding

Identifying Patient Subgroups That Are Most Likely To Benefit From Medications Used To Treat Alcohol Use DisorderK01AA028258 · NIAAA · YALE UNIVERSITY · PI WALLACH, JOSHUA DAVID · 2021 to 2025
$892k
NIAAA NIH HHS K01 AA028258
6 · The paper itself

Abstract

objectiveTo systematically identify, match, and compare treatment effects and study demographics from individual or meta-analysed observational studies and randomized controlled trials (RCTs) evaluating the same covid-19 treatments, comparators, and outcomes.

designMeta-epidemiological study. DATA SOURCES: National Institutes of Health Covid-19 Treatment Guidelines, a living review and network meta-analysis published in ELIGIBILITY CRITERIA FOR SELECTION OF STUDIES: RCTs in DATA EXTRACTION AND SYNTHESIS: Safety and efficacy outcomes from observational studies were identified and treatment effects for dichotomous (odds ratios) or continuous (mean differences or ratios of means) outcomes were calculated and, when possible, meta-analyzed to match the treatment effects from individual RCTs or meta-analyses of RCTs reported in

results17 new, independent meta-analyses of observational studies were conducted that compared hydroxychloroquine, lopinavir-ritonavir, or dexamethasone with an active or placebo comparator for any safety or efficacy outcomes in covid-19 treatment. These studies were matched and compared with 17 meta-analyses of RCTs reported in

conclusionsMeta-analyses of observational studies and RCTs evaluating treatments for covid-19 have summary treatment effects that are generally in agreement. Although our evaluation is limited to three covid-19 treatments, these findings suggest that meta-analyzed evidence from observational studies might complement, but should not replace, evidence collected from RCTs.

Indexed as

COVID-19 Drug TreatmentHydroxychloroquineDexamethasoneHumansLopinavirMeta-Analysis as TopicObservational Studies as TopicRandomized Controlled Trials as TopicRitonavirDexamethasoneHydroxychloroquineLopinavirRitonavir

Identifiers

PMID35537738
PMCPMC9086409

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.